Revolution Medicines, Inc. Common Stock

Day range

$181.00 – $188.30

Open

$186.99

Prev close

$186.99

Volume

1.08M

Market cap

$40.08B

Shares out

214.34M

P/E

—

P/S

—

P/B

15.38

P/FCF

—

ROE

-67.8%

ROA

-40.9%

Debt/Equity

0.19

Div yield

0.00%

As of Oct 23, 2026

• Credit facilityOct 13, 2026

  The Loan Agreement provides for a senior secured term loan facility of up to $750.0 million, consisting of three tranches of up to $250.0 million each.

• Lease agreementSep 1, 2026

  On August 27, 2026, Revolution Medicines, Inc. agreed to lease the entirety of four buildings located at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, comprising an aggregate of approximately 672,000 rentable square feet. The Company intends to use the Premises as its new headquarters.

• Product or service launchAug 26, 2026

  Once-daily oral RASONQUE tablets are now available in the United States for physicians to prescribe to eligible patients. The wholesale acquisition cost of RASONQUE is $39,800 for a 30-day supply, based on the recommended daily dose.

• Annual meeting resultsJun 22, 2026

  On June 18, 2026, the Company held its annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on three proposals... Proposal 1. The Company's stockholders elected two Class III directors to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected and qualified.

• Debt issuanceApr 17, 2026

  On April 17, 2026, Revolution Medicines, Inc. (the "Company") issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033 (the "Notes"). The Notes will accrue interest at a rate of 0.50% per annum, payable semi-annually in arrears on May 1 and November 1 of each year, beginning on November 1, 2026. The Notes will mature on May 1, 2033.

Days to cover

4.7

Short interest

11.93M

Avg volume

2.56M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight
  positiveGlobeNewswire Inc.· Oct 26, 2026
• These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead
  neutralThe Motley Fool· Oct 15, 2026
• Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
  positiveThe Motley Fool· Sep 11, 2026
• New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
  positiveGlobeNewswire Inc.· Sep 2, 2026
• Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
  positiveThe Motley Fool· Aug 28, 2026